Quinolones Global Market Report 2024

The quinolones market size has grown steadily in recent years. It will grow from $48.31 billion in 2023 to $50.65 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth observed in the historical period can be attributed to factors such as the demand for antibiotics and their usage, regulatory approvals, research and development activities, the competitive landscape within the pharmaceutical industry, and the expiration of patents.

The quinolones market size is expected to see steady growth in the next few years. It will grow to $61.51 billion in 2028 at a compound annual growth rate (CAGR) of 5.0%. The anticipated growth in the forecast period can be attributed to factors such as the emergence of new diseases, regulatory changes, global health policies, the increasing challenge of antibiotic resistance, and market expansion strategies. Key trends expected in the forecast period may include advancements or shifts in medical research, changes in healthcare policies, and evolving strategies to address antibiotic resistance.

The growth of the quinolones market is significantly attributed to the increasing incidence of infectious diseases. Infectious diseases, caused by microbes such as parasites, fungi, bacteria, and viruses, remain a global health challenge. Quinolones, widely employed in treating various bacterial infections such as tuberculosis and urinary tract infections, play a crucial role in addressing these health concerns. For example, data from 2022 provided by the Pan American Health Organization indicated that approximately 10.6 million people contracted tuberculosis (TB) in 2021, marking a 4.5% increase. Thus, the upsurge in infectious diseases is a driving force behind the growth of the quinolones market.

The anticipated rise in antimicrobial resistance contributes to the continued growth of the quinolones market. Antimicrobial resistance (AMR), the ability of microorganisms to resist the effects of antimicrobial drugs, poses a significant threat to public health. Quinolones, with their broad spectrum of activity and effectiveness against various bacteria, become a preferred choice in cases of limited options. Notably, in November 2022, the United Kingdom Health Security Agency reported a 2.2% increase in the predicted total number of severe antibiotic-resistant infections in England in 2021. This highlights the growing danger of antimicrobial resistance, which is propelling the demand for quinolones.

A prominent trend in the quinolones market is the emphasis on product innovation by major companies to sustain their market positions. For instance, in January 2023, Viatris, a US-based pharmaceutical company's South Korean branch introduced Dovprela, a novel treatment for drug-resistant tuberculosis. Dovprela, a three-drug regimen comprising bedaquiline, pretomanid, and linezolid (BPaL), offers a more rapid anti-tuberculosis effect, reducing the treatment period from 18-20 months to 5-6 months. This innovation addresses the pressing need for effective and efficient tuberculosis treatments.

Innovative products, such as fluoroquinolone antibiotic eye drops, are being introduced to drive revenues in the quinolones market. Fluoroquinolone antibiotic eye drops, a class of antibiotics targeting bacterial eye infections, contribute to ophthalmic health. For instance, Harrow Health Inc., a US-based pharmaceutical company, launched Vigamox in July 2023. This sterile ophthalmic solution, delivered in a 3-milliliter bottle, is indicated for the prevention of eye infections before and after surgery. Such innovative products cater to diverse medical needs and contribute to the market's growth.

In June 2023, Bausch + Lomb Incorporated, a US-based eye health company, acquired Novartis International AG for an undisclosed amount. Through this acquisition, Bausch + Lomb aims to restructure its pharmaceutical division, enhancing its scale and positioning it at the forefront of addressing ocular surface disorders. The acquisition diversifies Bausch + Lomb's product portfolio, introducing new opportunities such as libvatrep and AcuStream technology. Libvatrep is an experimental compound studied for treating chronic ocular surface pain, while AcuStream technology is an experimental device designed for accurate dosing and delivery of certain topical ophthalmic medications. Novartis International AG, based in Switzerland, is a pharmaceutical company with a global presence.

Major companies operating in the quinolones market report are Bayer AG, Novartis AG, Sanofi SA, Johnson & Johnson Services Inc., Merck & Co. Inc., LG Life Sciences, Allergan Inc., Pfizer Inc., Viatris Inc., Lupin Limited, Hikma Pharmaceuticals plc, Zydus Group, Bausch Health Companies Inc., KYORIN Holdings Inc., MerLion Pharmaceuticals GmbH, Teva Pharmaceutical Industries Ltd., GSK plc, AbbVie Inc., Zee Laboratories, Cipla Ltd., Bhavishya Pharmaceuticals, Geo Pharma Pvt. Ltd., Finecure Pharmaceuticals, Novus, AstraZeneca plc, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Hetero Drugs Ltd., Mylan N.V., Wockhardt Ltd.

North America was the largest region in the quinolones market in 2023. The regions covered in the quinolones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the quinolones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of quinolones include norfloxacin, ofloxacin, ciprofloxacin, gemifloxacin, and others. Norfloxacin, specifically a fluoroquinolone, is utilized for the treatment of diverse bacterial infections. Its applications extend to addressing conditions such as conjunctivitis and urinary tract infections, targeting both gram-positive and gram-negative pathogens. Quinolones are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The quinolones market research report is one of a series of new reports that provides, quinolones market statistics, including, quinolones industry global market size, regional shares, competitors with a quinolones market share, detailed, quinolones market segments, market trends and opportunities, and any further data you may need to thrive in the quinolones industry. This, quinolones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.